We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma

This study has been terminated.
(Slow accrual)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01878708
First Posted: June 17, 2013
Last Update Posted: March 6, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Leadiant Biosciences, Inc.
Information provided by (Responsible Party):
Philippe Armand, MD, PhD, Dana-Farber Cancer Institute
May 23, 2013
June 17, 2013
March 6, 2017
July 2013
February 2017   (Final data collection date for primary outcome measure)
Overall response rate (complete + partial response) in evaluable patients. [ Time Frame: 24 weeks ]
Same as current
Complete list of historical versions of study NCT01878708 on ClinicalTrials.gov Archive Site
  • Duration of response for patients with PR or CR [ Time Frame: 24 weeks ]
  • Grade 2 and above attributable toxicity of treatment. [ Time Frame: 24 weeks ]
  • Progression-free survival. [ Time Frame: 1 year ]
    This will be assessed in both evaluable patients and in responders.
  • Complete remission (CR) rate. [ Time Frame: 24 weeks ]
    This will be assessed both in the intent-to-treat and in the evaluable populations.
  • Partial remission (PR) rate. [ Time Frame: 24 weeks ]
    This will be assessed both in the intent-to-treat and in the evaluable populations.
  • The stable disease (SD) rates in this population and in the intent-to-treat population [ Time Frame: 24 weeks ]
  • Progressive disease (PD) rate. [ Time Frame: 24 weeks ]
    This will be assessed both in the intent-to-treat and in the evaluable populations.
  • Stable disease (SD) rate. [ Time Frame: 24 weeks ]
    This will be assessed both in the intent-to-treat and in the evaluable populations.
  • Overall survival [ Time Frame: 1 year ]
    This will be assessed in both evaluable patients and in responders.
Same as current
Not Provided
Not Provided
 
A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma
A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma
This is an open-label, single-arm pilot study of Oncaspar® with dexamethasone for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), excluding extranodal NK/T cell lymphoma (ENKTL). Patients will receive up to 8 courses of treatment.

This is an open-label, investigator-initiated, single-arm pilot study. Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) will receive Oncaspar® every 3 weeks up to a maximum of 8 courses or until disease progression or unacceptable toxicity. They will also receive dexamethasone 40mg daily for 4 days with every cycle. They will be restaged after 2 courses (6 weeks) and after 8 courses (24 weeks).

Both Oncaspar and dexamethasone have been used together to treat ALL and ENKTL, which is another subtype of T cell lymphoma. The combination may provide a collaborative attack against the cancer cell; moreover, the dexamethasone could also prevent some of the side effects of Oncaspar; especially allergic reactions. This study will test these two drugs together to determine if they are an effective treatment for T-Cell Lymphoma. Each drug is commercially available to the drug market.

Interventional
Early Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • T-Cell Lymphoma
  • Relapsed T-Cell Lymphoma
  • Refractory T-Cell Lymphoma
  • Drug: PEG-L-asparaginase
    Other Names:
    • Oncaspar
    • PEG-asparaginase
  • Drug: Dexamethasone acetate
    -dexamethasone 40mg daily for 4 days with every cycle.
Experimental: PEG-L-asparaginase/Dexamethasone
Patients will receive Oncaspar® (PEG-asparaginase) at a dose of 2,000 IU/m2 administered intramuscularly on day 3 of each 3 week cycle, with dexamethasone 40mg given orally on days 1-4.
Interventions:
  • Drug: PEG-L-asparaginase
  • Drug: Dexamethasone acetate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
2
February 2017
February 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must meet the following criteria on screening examination to be eligible to participate in the study:
  • Patients must have histologically confirmed peripheral T-cell lymphoma, with the diagnostic specimen reviewed at one of the DFHCC hematopathology laboratories. Eligible histologies include:
  • PTCL-NOS
  • Systemic T cell/null anaplastic large cell lymphoma (ALCL), regardless of Alk status
  • Angioimmunoblastic T-cell lymphoma (AITL)
  • Hepatosplenic (alpha-beta or gamma-delta) lymphoma (HSL)
  • Enteropathy-associated T-cell lymphoma (EATL)
  • Adult T-cell leukemia/lymphoma (ATLL), lymphomatous subtype
  • Subcutaneous panniculitis-like T-cell lymphoma
  • T-cell Prolymphocytic Leukemia (T-PLL)
  • Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as > 10 mm with spiral CT scan
  • Patients must have relapsed or progressed after at least 1 prior course of anti-lymphoma therapy.
  • Age 18-65 years.
  • ECOG performance status <2 (see Appendix A).
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Patients who exhibit any of the following conditions at screening will not be eligible for admission into the study.
  • Patients with cutaneous disease only are not eligible.
  • Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier to grade 1 or below (unless approved by the Study Chair).
  • Patients may not be receiving any other study agents at the time of first treatment.
  • History of treatment with an asparaginase agent.
  • Patients with a history of alcohol abuse, or patients unwilling or unable to remain completely abstinent of alcohol during the study period.
  • Hepatitis B or C seropositivity (except for hepatitis B with negative surface antigen and hepatitis B viral load).
  • Total bilirubin > institutional upper limit of normal (ULN), unless due to hemolysis or Gilbert's disease).
  • AST/ALT ≥ 3 x ULN.
  • History of pancreatitis, or amylase > ULN or lipase > ULN.
  • History of thromboembolic disease.
  • Grade 2 or above neuropathy.
  • Diabetes mellitus, unless it is type II diabetes adequately controlled with anti-diabetic agents (A1c < 7).
  • History of CNS hemorrhage or thrombosis. Patients with a history of CNS lymphomatous involvement are eligible only if their CNS disease is in remission at the time of study entry.
  • Uncontrolled intercurrent illness including, but not limited to uncontrolled active infection, symptomatic congestive heart failure (New York Hospital Association (NYHA) class II-IV, resulting in at least slight limitation of activity), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Inability to provide informed consent
  • Pregnancy or lactation.
  • Individuals with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
  • HIV-positive individuals on combination antiretroviral therapy are ineligible.
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01878708
13-165
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Philippe Armand, MD, PhD, Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Leadiant Biosciences, Inc.
Principal Investigator: Phillippe Armand, MD Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP